Search results for " effect"

showing 10 items of 7524 documents

Non-healing tongue ulcer in a rheumatoid arthritis patient medicated with leflunomide. An adverse drug event?

2017

Leflunomide is a member of the disease modifying anti-rheumatic drugs group used as a treatment modality in active rheumatoid and psoriatic arthritis. “Oral ulcers” are reported in 3-5% of leflunomide medicated rheumatoid arthritis patients with adverse events, but they are not described in detail in the literature. We present a case of an ulcer in the tongue of a rheumatoid arthritis patient managed with leflunomide and contemplate on its pathogenesis. Key words:Leflunomide, oral ulcer, DHODH.

musculoskeletal diseasesmedicine.medical_specialtyCase ReportOdontologíaDisease030207 dermatology & venereal diseases03 medical and health sciencesPsoriatic arthritis0302 clinical medicineTonguemedicineOral ulcersskin and connective tissue diseasesAdverse effectGeneral DentistryLeflunomide030203 arthritis & rheumatologyOral Medicine and Pathologybusiness.industry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludDermatology3. Good healthSurgerymedicine.anatomical_structureAdverse drug eventRheumatoid arthritisUNESCO::CIENCIAS MÉDICASbusinessmedicine.drugJournal of Clinical and Experimental Dentistry
researchProduct

Scientific evidence on the usefulness of intraarticular hyaluronic acid injection in the management of temporomandibular dysfunction

2010

Abstract Hyaluronic acid (HA) is found in high concentrations in cartilage and synovial fluid, and is an important component of the extracellular matrixes ? exerting joint lubrication and buffering actions thanks to its viscoelastic properties. The present study examines the scientific evidence found in the current literature on the usefulness of the intraarticular injection of HA in patients with temporomandibular dysfunction. A literature search was made up until May 2008 in the following databases: PubMed / MEDLINE. Of the articles found in the literature, the present review included 18 relevant studies on the application of HA in the temporomandibular joint (TMJ). The quality, level of …

musculoskeletal diseasesmedicine.medical_specialtyHyaluronic acidMEDLINETemporomandibular joint abnormalities.BioinformaticsScientific evidenceInjections Intra-Articularchemistry.chemical_compoundHyaluronic acidTemporomandibular joint abnormalitiesmedicineSynovial fluidHumansMalformacions de l'articulació temporomandibularHyaluronic AcidGeneral Dentistrybusiness.industryCartilageTherapeutic effectEvidence-based medicineTemporomandibular Joint Dysfunction Syndrome:CIENCIAS MÉDICAS [UNESCO]Àcid hialurònicSurgeryTemporomandibular jointmedicine.anatomical_structureOtorhinolaryngologychemistryUNESCO::CIENCIAS MÉDICASSurgerybusiness
researchProduct

Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicent…

2017

Summary Background Little evidence-based information is available to guide the treatment of oligoarticular juvenile idiopathic arthritis. We aimed to investigate whether oral methotrexate increases the efficacy of intra-articular corticosteroid therapy. Methods We did this prospective, open-label, randomised trial at ten hospitals in Italy. Using a concealed computer-generated list, children younger than 18 years with oligoarticular-onset disease were randomly assigned (1:1) to intra-articular corticosteroids alone or in combination with oral methotrexate (15 mg/m 2 ; maximum 20 mg). Corticosteroids used were triamcinolone hexacetonide (shoulder, elbow, wrist, knee, and tibiotalar joints) o…

musculoskeletal diseasesmedicine.medical_specialtyPopulationArthritisInjections Intra-Articular03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesInternal medicinemedicinemedia_common.cataloged_instanceHumans030212 general & internal medicineProspective StudiesEuropean unionAdverse effecteducationmedia_common030203 arthritis & rheumatologyeducation.field_of_studybusiness.industryMedicine (all)General MedicineMethylprednisolone acetateJuvenile idiopathic arthritismedicine.diseaseArthritis JuvenileSurgeryClinical trialMethotrexateTreatment OutcomeItalySettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAMethotrexateOligoarticular Juvenile Idiopathic Arthritisbusinessmedicine.drug
researchProduct

MINIMIZING INFLIXIMAB TOXICITY IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

2008

Abstract Background Infliximab is a widely used biological agent for the treatment of inflammatory bowel disease, and has a favorable risk/benefit ratio. Aim It is useful to know that patients treated with infliximab are exposed to developing adverse events that could be reduced with a prudent and a rational clinical approach and by optimizing the treatment protocol. Methods PubMed (including Epub) was searched in October 2006 and again in March 2007. Results The high immunogenic potential of infliximab determines the antibodies that inhibit the effect of infliximab and the appearance of subsequent acute and delayed infusion reactions. Infliximab has an immunomodulatory effect, thus increas…

musculoskeletal diseasesmedicine.medical_specialtyTuberculosisInflammatory bowel diseaseGastroenterologyDrug Administration SchedulePharmacotherapyimmune system diseasesInternal medicinemedicineHumansImmunologic Factorsskin and connective tissue diseasesAdverse effectClinical Trials as TopicHepatologybusiness.industryTumor Necrosis Factor-alphaGastroenterologyAntibodies Monoclonalmedicine.diseaseInflammatory Bowel DiseasesInfliximabInfliximabLymphomastomatognathic diseasesHeart failureToxicityDrug Therapy CombinationbusinessImmunosuppressive Agentsmedicine.drug
researchProduct

Abatacept as Adjunctive Therapy in Refractory Polymyalgia Rheumatica.

2021

Glucocorticoids (GCs) are the mainstay of treatment for patients with polymyalgia rheumatica (PMR).1 Despite their efficacy, GCs are associated with well-known adverse events and a substantial proportion of patients with PMR do not respond adequately, or are refractory, to initial GC treatment. GC-sparing agents in PMR are limited to methotrexate (MTX).1.

musculoskeletal diseasesmedicine.medical_specialtyeducationImmunologyGiant Cell ArteritisPolymyalgia rheumaticaAbataceptDiagnosis DifferentialRheumatologyRefractoryimmune system diseasesInternal medicinemedicineImmunology and AllergyHumansskin and connective tissue diseasesAdverse effectbusiness.industryAbataceptmedicine.diseaseCombined Modality TherapyPolymyalgia RheumaticaMethotrexatebusinesshormones hormone substitutes and hormone antagonistsmedicine.drugThe Journal of rheumatology
researchProduct

Beneficial Intervertebral Disc and Muscle Adaptations in High-Volume Road Cyclists

2019

PURPOSE: Cycling is widely practiced as a mode of transportation, a leisurely pursuit and a competitive sport. Approximately half of cyclists experience low back pain. Yet, there has been limited study of spine tissue adaptations due to cycling. METHODS: To investigate potential risk factors for spinal pain, we compared 18 high-volume cyclists (>150 km per week for ³5 years) to 18 height-matched non-sporting referents. Participants had no history of spinal pathology. Magnetic resonance imaging was used to quantify intervertebral disc (IVD) morphology and hydration; and psoas, erector spinae, quadratus lumborum and multifidus muscle size and fat content. Endurance of trunk muscles (flexors a…

musculoskeletal diseasesnikamavälilevycyclingintervertebral disklihaksetpyöräilijätmusculoskeletal systembackselkämusclescyclistshuman activitiespyöräilyfysiologiset vaikutuksetphysiological effects
researchProduct

Hippocampal event-related potentials to pitch deviances in an auditory oddball situation in the cat: experiment I.

1995

Hippocampal event-related potentials (ERP) in the areas CA1, CA3, and dentate fascia (Df) were recorded in cats during an oddball situation when pitch deviant tones occurred in a series of standard tones. When difference waves were calculated by subtracting ERPs to the standard tones from those to the deviant tones, no clear N40d, corresponding to a cat analogue of the human mismatch negativity (MMN) observed in earlier studies, could be detected. Instead, a prominent later negativity (N130d) was observed. A possible extra-hippocampal source of the process reflected by the MMN-like negativity, and a relation between an orienting response (OR) and the N130d are discussed.

musculoskeletal neural and ocular physiologyGeneral NeuroscienceAuditory oddballHippocampusMismatch negativityNegativity effectHippocampal formationbehavioral disciplines and activitiesHippocampusElectrodes ImplantedOrienting responseElectrophysiologyNeuropsychology and Physiological PsychologyAcoustic StimulationEvent-related potentialPhysiology (medical)OrientationDentate GyrusCatsEvoked Potentials AuditoryAnimalsPsychologyNeurosciencepsychological phenomena and processesInternational journal of psychophysiology : official journal of the International Organization of Psychophysiology
researchProduct

Inhibition of xanthine oxidase to prevent statin-induced myalgia and rhabdomiolysis

2015

Although statins remain the cornerstone of lipid-lowering therapy for reducing the burden of atherosclerotic vascular disease, their administration has been associated with muscle-related adverse effects, including myalgia and rhabdomyolysis. Such adverse events are probably due to reduced antioxidant defenses associated with fewer intermediate metabolites in the cholesterol synthesis pathway. We hypothesize that the concomitant inhibition of xanthine oxidase via coadministration of allopurinol with statins could diminish reactive oxygen species (ROS)-related muscle damage, which would have in turn have positive effects on both the incidence of muscle-related adverse events and cardiovascul…

myalgiaXanthine OxidaseAntioxidantStatinUbiquinonemedicine.drug_classAllopurinolmedicine.medical_treatmentHypercholesterolemiaAllopurinolPharmacologyRhabdomyolysischemistry.chemical_compoundAnimalsHumansMedicineXanthine oxidaseEnzyme InhibitorsXanthine oxidaseAdverse effectchemistry.chemical_classificationReactive oxygen speciesLipid-lowering drugsbusiness.industryMyalgiamedicine.diseasechemistryCardiovascular DiseasesHydroxymethylglutaryl-CoA Reductase Inhibitorsmedicine.symptomReactive Oxygen SpeciesCardiology and Cardiovascular MedicinebusinessRhabdomyolysisBiomarkersmedicine.drugAtherosclerosis
researchProduct

Open-label ODYSSEY APPRISE study: Interim data from the first 843 participants

2018

Background PCSK9 inhibitors (PCSK9i) have been recommended by the ESC/EAS Task Force in very high risk subjects with ASCVD and those with heterozygous familial hypercholesterolemia (HeFH) with persistent high LDL-C levels despite maximally tolerated LLT. Purpose ODYSSEY APPRISE (NCT02476006) is the first study to assess efficacy and safety at Week (W) 12 of the PCSK9i alirocumab (ALI) in a real-life setting prior to commercial availability. Methods APPRISE was an open-label, single-arm study, conducted in 16 European countries and Canada. Subjects with inadequately controlled lipid levels despite maximally tolerated LLT were included. Based on physician's judgment, participants received eit…

myalgiamedicine.medical_specialtyErythemabusiness.industryFamilial hypercholesterolemia030204 cardiovascular system & hematologymedicine.disease03 medical and health sciences0302 clinical medicineTolerabilityInternal medicineClinical endpointmedicineBack painmedicine.symptomCardiology and Cardiovascular MedicineAdverse effectbusiness030217 neurology & neurosurgeryAlirocumabArchives of Cardiovascular Diseases Supplements
researchProduct

NEO1 and NEO-EXT studies: Long-term safety of repeat avalglucosidase alfa dosing for 4.5 years in late-onset Pompe disease patients

2019

Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of repeat avalglucosidase alfa dosing (5, 10, or 20 mg/kg qow) for 6 months were evaluated in NEO1 (NCT01898364) in late-onset Pompe disease patients either treatment-naive (Naive) or having received alglucosidase alfa for ≥9 months (Switch). In NEO-EXT (NCT02032524), an ongoing NEO1 extension, long-term safety and pharmacokinetics of repeat avalglucosidase alfa dosing will be monitored over 6 years. Interim safety results after 4.5 years of NEO-EXT are reported here. Mean ages at NEO1 enrollment were: Naive: 44.8 (SD:20.3, range:20-78) years and Switch: 46.7 (SD:14.1, range:21-68) years. Of the 24 NEO1 parti…

myalgiamedicine.medical_specialtyNauseabusiness.industryEndocrinology Diabetes and MetabolismBiochemistryRashEndocrinologyTolerabilityInternal medicinePharmacodynamicsGeneticsmedicineDosingmedicine.symptomAdverse effectbusinessMolecular BiologyAlglucosidase alfamedicine.drugMolecular Genetics and Metabolism
researchProduct